Glycoproteins that relate to the occurrence and development of many diseases such as tumors, cardiovascular disease, and diabetes will enter the blood circulation after getting shed from the cells, which can work as the biomarkers to provide useful information for clinical diagnosis. Those features make therapeutic glycoprotein currently a growing stream in the pharmaceutical industry, resulting in a climbing share of glycoengineering service in the biopharmaceutical market.
To help the researchers and pharmaceutical partners with discovering the most effective therapeutic glycoprotein, Creative Biolabs provides solutions on glycosylation, the most widely applied posttranslational modification (PTM) approach to change protein function and measure the recombinant biopharmaceutical immunogenicity. Based upon the efficient glycoengineered expression platforms (glyco-engineered mammalian cell expression system, glyco-engineered pichia pastoris expression system, and glyco-engineered plant-based expression system), Creative Biolabs is fully competent to handle the requests of therapeutic glycoprotein development and glycoengineering of antibody/cell line.
Creative Biolabs has updated the generally applied mammalian cell expression with glyco-engineered Chinese hamster ovary (CHO) cells and glyco-engineered human embryonic kidney 293 (HEK293) cells for glycoprotein production, which can guarantee the natural folding and sugar chain composition of glycoprotein, and meanwhile enhancing the glycoprotein expression level, eradicating the humanization problem fundamentally.
After modifications like the knock-out of och1 gene and introduction of mannosidase, the Glyco-engineered Pichia pastoris Expression System shows merits (short production period, cost-effectiveness, high yield, easy operation and scaling up, etc.), which integrates the strengths of Escherichia coli, mammalian cells, and yeast, applicable to fulfilling gene sequence design of target glycoprotein, condon and synthesize gene optimization, and else.
To elevate the potency, safety, and stability of therapeutic proteins and eliminate the immunogenicity of plant-specific N-glycans, the Glyco-engineered Plant-based Expression System is improved, which meets the demands of standard plant N-glycans, afucosated N-glycans and humanized N-glycans, without changing the amino acid sequence of the target protein. The platform can generate glycoproteins with on-demand homogeneous glycans at high speed and on large scales.
Except for the glycoengineering services, other solutions at Creative Biolabs include but are unlimited to custom synthesis, glycoprotein analysis, anti-glycoprotein antibody development, development of glyco-based vaccines, supported by the high-end technologies and skilled technicians, which can be customized upon requests, and offered at a reasonable price. More relevant information can be accessed at https://www.creative-biolabs.com/glycoprotein.
About Creative Biolabs
Creative Biolabs is a biotechnology solution provider in the area of therapeutic glycoprotein, who is specialized in producing glycoprotein and analysis services. With a group of professionals and the high-end production platforms (such as bacteria, mammalian cells, insect cells, yeast cells, and plant cells), Creative Biolabs can handle glycoprotein production projects covering a wide range of purposes.